- Home
- MDRR vs ERNA Comparison
MDRR vs ERNA Comparison
Compare MDRR & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | ERNA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 10.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDRR | ERNA |
|---|---|---|
| Price | $13.00 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.6K | ★ 46.1K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,098,461.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $9.55 | $1.09 |
| 52 Week High | $15.00 | $14.40 |
Technical Indicators
Market Signals| Indicator | MDRR | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 49.33 |
| Support Level | $12.66 | $1.22 |
| Resistance Level | $13.62 | $1.50 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 45.28 | 65.00 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.